Osteopore specialises in the production of 3D printed bioresorbable implants that are used in conjunction with surgical procedures to assist with the natural stages of bone healing.
Osteopore is involved in designing, developing and marketing bioresorbable polymer implants for neurosurgical, orthopaedic, and maxillofacial surgery use.
Osteopore products are made of a US FDA approved polymer called polycaprolactone (PCL). PCL is bioresorbable, malleable, slow-degrading and possesses mechanical strength similar to trabecular bone.
Mark Leong, Non Executive Chairman
Mr Leong is a Fellow of the Association of Chartered Certified Accountants (ACCA), Chartered Accountant of the Institute of Singapore Chartered Accountants (ISCA) and Member of the Singapore Institute of Directors (SID).
An Australian Permanent Resident with prior ASX board experience, Mr Leong has more than 22 years of corporate, management and directorship experience in a broad range of functions in a diverse range of industries having undertaken several C-suite roles (CEO, COO, & CFO) in several private as well as listed companies and presently serves as Independent Director in 3 Singapore listed companies.
Professor Teoh Swee Hin, Non Executive Director
Professor Teoh is presently the Chairman, Singapore Academy, Asia Regulatory Professional Association (ARPA). He sits in as board of editors Tissue Engineering, Journal of Tissue Engineering and Regenerative Medicine, Journal of Mechanical Behaviour of Biomedical Materials, Journal of Oral & Maxillofacial Research and Proceedings of the Institution of Mechanical Engineers Part H: Journal of Engineering in Medicine.
Daniel Ow, Non Executive Director
Mr Ow has over twenty years of international experience across multiple industries, including infrastructure, resources, property and fast-moving consumer goods. Mr Ow has held several accounting and management roles with large multinational corporations and is a Certified Practising Accountant (CPA), Australia. He is currently Manager Financial Business Partners at Perth Airport. Along with professional experience in investor relations, he also served as Trustee Director on the Rio Tinto Staff Superannuation Fund (now merged with Equip Super).
Khoon Seng Goh, CEO
Mr Goh’s 30-year career spans both start-ups and global multinational corporations, with responsibilities in research & development, manufacturing, regional sales and marketing, and country management. Prior to joining Osteopore Mr Goh spent over 20 years with Medtronic plc (Medtronic plc is the world’s largest medical device company) and Edwards Lifesciences Asia in various senior management roles.
Mr Goh has been a Director of Osteopore Pte Ltd, since 2015 and has been involved in all aspects of the Company.
Mr Goh holds a Masters in Engineering (National University of Singapore) and post graduate diploma with Chartered Institute of Marketing (UK).